Abstract
The antithrombin III (AT III) concentration in plasma was measured in 63 patients on oral anticoagulant treatment (mean age 57.7 years), 26 healthy laboratory controls (mean age 28 years), and 21 patients attending the hypertensive clinic who had never been on oral anticoagulants (mean age 50 years). Three methods were used to measure AT III: a coagulation assay, a chromogenic substrate assay, and an immunological assay. In patients on oral anticoagulants, the mean values for AT III in the three assays were: 124%, 107%, and 96% respectively. The mean AT III concentration in laboratory staff was 103.4%, 94%, and 104.1% for the three assays; patients attending the hypertensive clinic had AT III concentrations indistinguishable from those in patients on oral anticoagulants: 117.9%, 110.5%, and 93.9%. The difference between both patient groups and laboratory staff was statistically highly significant, but no difference was demonstrated between patients on anticoagulant treatment and those not receiving it. Our results show that the increase in the functional AT III concentration (measured by coagulation and chromogenic assays) observed in patients on oral anticoagulants is probably due to the effects of age and underlying disease rather than to the anticoagulant treatment itself.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Abildgaard U., Gravem K., Godal H. C. Assay of progressive antithrombin in plasma. Thromb Diath Haemorrh. 1970 Oct 31;24(1):224–229. [PubMed] [Google Scholar]
- Barrowcliffe T. W., Johnson E. A., Thomas D. Antithrombin III and heparin. Br Med Bull. 1978 May;34(2):143–150. doi: 10.1093/oxfordjournals.bmb.a071484. [DOI] [PubMed] [Google Scholar]
- Chan T. K., Chan V. The effect of venous occlusion on antithrombin III, plasminogen activator and fibrinogen degradation product (fragment E) levels. Thromb Res. 1979;14(4-5):525–534. doi: 10.1016/0049-3848(79)90108-7. [DOI] [PubMed] [Google Scholar]
- Davies J. A., McNicol G. P. Blood coagulation in pathological thrombus formation and the detection in blood of a thrombotic tendency. Br Med Bull. 1978 May;34(2):113–121. doi: 10.1093/oxfordjournals.bmb.a071480. [DOI] [PubMed] [Google Scholar]
- Laurell C. B. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem. 1966 Apr;15(1):45–52. doi: 10.1016/0003-2697(66)90246-6. [DOI] [PubMed] [Google Scholar]
- Marciniak E., Gockerman J. P. Heparin-induced decrease in circulating antithrombin-III. Lancet. 1977 Sep 17;2(8038):581–584. doi: 10.1016/s0140-6736(77)91429-5. [DOI] [PubMed] [Google Scholar]
- Meade T. W., North W. R., Chakrabarti R., Haines A. P., Stirling Y. Population-based distributions of haemostatic variables. Br Med Bull. 1977 Sep;33(3):283–288. doi: 10.1093/oxfordjournals.bmb.a071448. [DOI] [PubMed] [Google Scholar]
- Odegard O. R., Lie M., Abildgaard U. Heparin cofactor activity measured with an amidolytic method. Thromb Res. 1975 Apr;6(4):287–294. doi: 10.1016/0049-3848(75)90078-x. [DOI] [PubMed] [Google Scholar]
- Wessler S., Gitel S. N., Bank H., Martinowitz U., Stephenson R. C. An assay of the antithrombotic action of warfarin: its correlation with the inhibition of stasis thrombosis in rabbits. Thromb Haemost. 1979 Feb 15;40(3):486–498. [PubMed] [Google Scholar]
- Yue R. H., Gertler M. M., Starr T., Koutrouby R. Alteration of plasma antithrombin III levels in ischemic heart disease. Thromb Haemost. 1976 Jun 30;35(3):598–606. [PubMed] [Google Scholar]